CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CG Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$59.96+0.11 (+0.18%)
Close on Oct 19, 2026
- Market cap
- $5.29B
- P/E (TTM)
- –
- Dividend yield
- –
CG Oncology, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -4056.2%
- Net margin
- -3602.7%
- Return on equity, FY2025
- -21.7%
Financial strength
- Current ratio
- 22.22
- Debt to equity
- 0.00
- Debt to assets
- 0.3%
- Cash to current liabilities
- 41.6%
Valuation
- P/E ratio
- –
- Price to sales
- 849.14
- Price to book
- 5.14
- Dividend yield
- –